Stubbing out tobacco-funded research
A few weeks from now, the University of California and Stanford University may both institute across-the-board bans on tobacco-industry research funding, a sign of the latest struggle between academic integrity and university buckraking to play out across higher education.
The proponents of the ban have a simple point: Tobacco companies sell legal products that kill millions of people every year and for decades have distorted scientific research in order to deflect threats to their business. By… Continue Reading
Health and science roundup: Amgen, generic biologics, the origins of white people and more
Amgen’s anemia rollercoaster — Biotechnology titan Amgen may have dodged a bullet when a study released Thursday showed that its anemia drug Aranesp didn’t shorten the lives of patients, after several other studies had suggested the opposite. But its anemia franchise isn’t out of the woods yet. A Wednesday report in the Journal of the American Medical Association revealed that for-profit dialysis clinics prescribe far higher doses of anemia drugs to their patients than do their non-profit… Continue Reading
Health and science roundup: Amgen, generic biologics, the origins of white people and more
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
Amgen’s anemia rollercoaster — Biotechnology titan Amgen may have dodged a bullet when a study released Thursday showed that its anemia drug Aranesp didn’t shorten the lives of patients, after several other studies had suggested the opposite. But its anemia franchise isn’t out of the… Continue Reading